Abstract
Long-acting injectable cabotegravir plus rilpivirine offers an alternative to daily oral antiretroviral therapy, but insurance-related barriers can disrupt implementation. We examined the frequency and impact of insurance changes in a United States cohort and found that nearly half of patients experienced insurance changes, which could lead to delayed injections.